Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
M.D. Anderson Cancer Center
Northwestern University
Vanderbilt-Ingram Cancer Center
Dana-Farber Cancer Institute
Genentech, Inc.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Either bronchioloalveolar cell carcinoma or a variant thereof after review
Clinical stage IIIB (malignant pleural or pericardial effusion) or IV or recurrent/medically inoperable disease
Measurable or evaluable indicator lesions
No prior or one chemotherapy regimen for NSCLC
Three weeks since last chemotherapy, and three weeks since prior radiation therapy to a major bone-marrow containing area
Karnofsky performance status \> or = to 80% OR ECOG performance status ≤ or = to 1
Life expectancy \> or = to 8 weeks
Adequate hematologic, renal and/or hepatic function: WBC \> or = to 3,000/ul, hemoglobin \> or = to 9.0 g/dl, platelet count \> or = to 100,000/ul, total bilirubin \< or = to 1.0 mg/dl, AST \< than or = to 2.5 X UNL, creatinine \< or = to 1.5 mg/dl or Clcr \> or = to 55ml/min.
Effective contraception
You may not be if
Prior exposure to OSI-774 or other treatments targeting the HER family axis (e.g.-trastuzumab, ZD1839, C225, etc.)
Two or more prior chemotherapy regimens
Concurrent active cancer
Uncontrolled central nervous system metastases (i.e. any known CNS lesion which is radiographically unstable, symptomatic and/or requiring escalating doses of corticosteroids)
Pregnant or lactating women
Malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
Prior systemic cytotoxic chemotherapy for other malignant disease
Significant medical history or unstable medical condition (unstable systemic disease: congestive heart failure, recent MI, unstable angina, active infection, uncontrolled hypertension).
